All Posts

NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and…

Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims…

(MedPage Today) — Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) products sold through the…

(MedPage Today) — Note that some links may require registration or subscription.
GLP-1 receptor agonists may increase the risk of bone and tendon injuries along with conditions such as osteoporosis and gout, a retrospective study suggested. …

Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, according to a small new study.

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial,” published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies.

(MedPage Today) — Initiation of a GLP-1 receptor agonist was tied to lower risks of several substance use disorders (SUDs) in adults with type 2 diabetes, according to a target trial emulation using data on veterans.
In patients without a history…

South San Francisco, CA — March 5, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493…

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, drinking and opioid use disorders and addiction.

A year after stopping taking weight-loss drugs such as Ozempic and Wegovy, people regain—on average—60% of their lost weight. But beyond this, their regained weight plateaus, with individuals managing to keep off 25% of the weight lost to treatment, say researchers at the University of Cambridge. The work appears in eClinicalMedicine.

Research led by Penn Dental’s Henry Daniell investigates the use of a lettuce-based, plant-encapsulated delivery platform as a new oral delivery of two GLP-1 drugs previously approved by the FDA in injectable form.

Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among patients of different ages, races, and starting weights, with women benefiting somewhat more than men, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

Here’s a summary of the major announcements and trends from the 44th Annual JP Morgan Healthcare Conference in San Francisco (January 12–15, 2026) specifically in

JP Morgan 2026: Obesity & GLP-1 Therapies Take Center StageWhat the Latest Deals and Data Mean for the Future of Metabolic MedicineThe J.P. Morgan Healthcare

Here are the **highlights from Day 2 of the JP Morgan Healthcare Conference (San Francisco) specifically related to obesity, weight-gain therapies, and related drug developments

JP Morgan Healthcare Conference – Day 3 Highlights (Obesity & Metabolic Therapies)1. Shift From “Weight Loss” to Chronic Metabolic DiseaseDay 3 discussions made it clear

Some people will get itching at the site of injection of the GLP-1 drugs. This is not common but is irritating. There are some things you can do to lessen the severity of the reaction.

President Trump’s plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular GLP-1 weight loss drugs.

A framework published by the European Association for the Study of Obesity (EASO) that addresses the pharmacological treatment of obesity and its complications. This framework proposes a new

Weight-loss surgery dramatically outperformed GLP-1 medications in improving longevity and reducing heart, kidney, and eye complications for people with obesity and diabetes. Over 10 years, patients lost far more weight and required fewer medications. Experts say surgery continues to offer survival advantages even in the age of potent obesity drugs.

The provided source explores the increasing use of GLP-1 receptor agonists like semaglutide and liraglutide in individuals with HIV. It highlights that these medications are beneficial for addressing obesity

A Washington Post article talks about the Trump administration experiment to expand Medicare and Medicaid coverage for GLP-1 weight loss drugs like Ozempic, potentially benefiting millions of Americans

The provided text describes glucagon-like peptide-1 (GLP-1), detailing its production and the wide array of organs and systems it affects. Primarily, GLP-1 is generated in the intestinal

This JAMA article provides comprehensive guidance for clinicians on integrating diet and physical activity when prescribing GLP-1 receptor agonists for weight management. It outlines strategies for monitoring and

This patient-focused guide from JAMA Internal Medicine provides essential information for individuals utilizing GLP-1 medications for weight loss. It outlines the medications’ functions and offers practical dietary advice through a “MEAL” plan, emphasizing muscle

The practice of compounding pharmacies adding various supplements to GLP-1 receptor agonist formulations like semaglutide or tirzepatide is very common in the United States. These additions, which

“FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications.

A systematic review investigating the relationship between adiposity measures and the risk of developing colorectal cancer (CRC), building upon existing research that often relies solely on Body Mass

This source explores the impact of semaglutide, a weight loss medication, on muscle mass, glucose regulation, and bone health in adults with obesity. It highlights

This academic article presents a cost-effectiveness analysis of tirzepatide, a medication for managing overweight and obesity, comparing it against lifestyle modification (LSM) alone. Researchers used a simulation model to project lifetime health

A systematic review and meta-analysis of 85 prospective studies, examining the long-term impact of physical activity (PA) patterns throughout adulthood on mortality. The authors aimed to understand how consistent, increasing,

The source discusses research indicating that postmenopausal women on hormone therapy (HT) experience significantly greater weight loss when treated with tirzepatide, an obesity medication, compared